Isomorphic Labs kicks off 2024 with two pharmaceutical collaborations - Isomorphic Labs
Isomorphic Labs kicks off 2024 with two pharmaceutical collaborations
Source: isomorphiclabs.com
Coding excursions
Anonymity with encryption At Outcomes Engine we are working on techniques to gather data from learners, analyse the data, and share the data whilst maintaining anonymity. I was involved in some work in my previous company (pharmaceutical) with the security of personal data - in our case it was data...
Biopharma futures
I've been looking at a few industry reports on the future of biopharma as part of a course I'm on with INSEAD Business School on Business Strategy and Financial Performance. I thought I'd share some of my ramblings on Biopharma Futures. Expectations are high Pharmaceutical
companies are operating...
Source: agnate.co.uk
What does the future of work look like for pharma?
The COVID-19 pandemic has accelerated changes to our working world. What does this mean for pharma, and what must the industry do to keep pace? PwC - future of work for pharma costs - pressures on efficienct, increasing R&D costs sustainability and societal impact - pressure on companies to address...
Source: pwc.co.uk
The future of biopharma
Shifts in how diseases are diagnosed and prevented, custom treatments, curative therapies, digital therapeutics, and precision intervention could upend current business models in biopharma. Deloitte's Five forces to 2040 Prevention and early detection Customized treatments - interventions for very...
Source: deloitte.com
Factors affecting the uptake of new medicines: a systematic literature review - BMC Health Services Research Lublóy, Ágnes.
"This systematic literature review has provided insights into the factors that affect new drug uptake—primarily, doctors’ scientific orientation, prescribing habits, exposure to pharmaceutical marketing, and interpersonal communication." "Background The successful diffusion of new drugs is crucial...
Source: biomedcentral.com
The leader's brain: Neuroscience in the workplace
The brain rarely fires on all cylinders even at the best of times - what more during a pandemic?
Source: reuters.com
Outgoing U.N. aid chief slams G7 for failing on vaccine plan
Outgoing U.N. aid chief Mark Lowcock slammed the Group of Seven wealthy nations on Monday for failing to come up with a plan to vaccinate the world against COVID-19, describing the G7 pledge to provide 1 billion doses over the next year as a "small step."
Source: reuters.com
Quantum computing and pharmaceutical research
"Theoretically, quantum computers can prove more powerful than any supercomputer. And recent moves from computer giants such as Google and pharmaceutical titans such as Roche now suggest drug discovery might prove to be quantum computing’s first killer app." In January this year Boehringer-Ingelheim...
Source: ieee.org
Imperial College's COVID-19 modelling
Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand. "We show that in the UK and US context, suppression will minimally require a combination of social distancing of the entire population, home isolation of cases and household quarantine of their...
Source: imperial.ac.uk
Coronavirus COVID-19 SARS-CoV-2 information
A collection of information sources for COVID-19. The NHS 111 online COVID-19 service. The first point of call for someone in the UK who thinks they have symptoms or have been exposed whilst travelling. The NHS Coronavirus COVID-19 information webpage. UK Government's Coronavirus action plan. Public...
Eisai launches a digital health solution on Amazon Alexa for children with a rare form of epilepsy - Lennox-Gastaut Syndrome.
It marks the first time Pharmaceutical company Eisai has moved beyond medications and into digital health. The company’s Amazon Alexa skill – Ella the Jellyfish – has been developed for children with Lennox-Gastaut Syndrome (LGS) and was created with input from patients, their families and caregivers.
Source: epmmagazine.com
Publication bias is a challenge in science and a criticism of the influence of industry.
Publication bias is a challenge in science and a criticism of the influence of industry. In the domain of biosciences and drug development more accountability (e.g. the FDAAA 2007), editorial and peer-review training (as suggested by the Cochrane Collaboration), and statistical techniques (as championed...
A critical makeover for pharmaceutical companies: Overcoming industry obstacles with a cross-functional strategy. PwC
A critical makeover for pharmaceutical companies: Overcoming industry obstacles with a cross-functional strategy. PwC report. Going all "cross-functional" or "breaking down silos"?
"Compounding the external obstacles, however, is the internal culture of most pharma companies. This is an industry...
Source: pwc.com
Development of new antibiotics encouraged with new pharmaceutical payment system: The NHS will test the world's first ‘subscription’
Development of new antibiotics encouraged with new pharmaceutical payment system: The NHS will test the world's first ‘subscription’ style payment model to incentivise pharmaceutical companies to develop new drugs for resistant infections.
"The new trial will be led by the National Institute for...
Source: www.gov.uk
EU Trials Tracker — Who's not sharing clinical trial results? : By law, all clinical trials on the European Union
EU Trials Tracker — Who's not sharing clinical trial results?
:
By law, all clinical trials on the European Union Clinical Trials Register
(EUCTR) must report their results in the registry within a year of completion.
This site tracks which universities and pharmaceutical companies are...
Source: trialstracker.net
Early phase drug trial claims a breakthrough in Huntington disease. IONIS-HTT is an antisense "gene-silencing" compound,
Early phase drug trial claims a breakthrough in Huntington disease. IONIS-HTT is an antisense "gene-silencing" compound, injected in to CSF and designed to reduce the production of all forms of the huntingtin (HTT) protein, which in its mutated variant (mHTT) is responsible for Huntington's Disease....
Source: reuters.com
Police raid Merck pharmaceutical plant amid mysterious drug crisis: Is something wrong with hormone therapy or are patients
Police raid Merck pharmaceutical plant amid mysterious drug crisis: Is something wrong with hormone therapy or are patients over-reacting?
Source: arstechnica.com
1 in 12 doctors accepts payment from pharmaceutical companies related to opioids: One in twelve physicians -- and nearly
1 in 12 doctors accepts payment from pharmaceutical companies related to opioids: One in twelve physicians -- and nearly one in five family medicine physicians -- accepted payments from pharmaceutical companies related to opioids, according to a new study out of Boston Medical Center's Grayken Center...
Source: eurekalert.org
Online GP service Push Doctor Limited not providing safe care, according to CQC: Following a comprehensive inspection, the
Online GP service Push Doctor Limited not providing safe care, according to CQC: Following a comprehensive inspection, the Care Quality Commission has reported that online GP service Push Doctor Limited was not providing safe care in accordance with current regulations.
Source: pharmaceutical-journal.com
RSS feed